Lupron

(Reuters) - Abbott Laboratories Inc <ABT.N> plans to split off its pharmaceuticals business into a separate publicly traded company to increase Wall Street's focus on the remaining diversified medical product line, lifting shares 3.8 percent.

NEW YORK (Reuters) - Interest in Dendreon Corp's Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's more-convenient and faster-acting Zytiga treatment, according to some doctors and industry analysts.

LOS ANGELES (Reuters) - Options for treating prostate cancer are expanding with the advent of novel, and more expensive, medicines, with key data expected soon for what could be one of the biggest new drugs.

NEW YORK (Reuters Health) - Older men who opt for hormone-blocking therapy to treat prostate cancer might be slightly raising their risk of developing cataracts, hints new research.

NEW YORK (Reuters Health) - Men who opt for hormone-blocking therapy to treat prostate cancer may be increasing their risk of developing colon cancer, hints a study published this week in the Journal of the National Cancer Institute.

NEW YORK (Reuters Health) - Men who opt for hormone-blocking therapy to treat prostate cancer may be increasing their risk of developing colon cancer, hints a study published this week in the Journal of the National Cancer Institute.

WASHINGTON (Reuters) - Hormone treatments for prostate cancer need new warnings about a small increased risk of diabetes and heart problems including sudden death, U.S. health officials said on Wednesday.

WASHINGTON (Reuters) - The U.S. Food and Drug Administration is examining if certain hormone treatments for men with prostate cancer pose a greater risk of diabetes or heart problems than other therapies.

The Food and Drug Administration is looking into data suggesting a group of prostate cancer drugs increase the risk of diabetes and heart disease.

FDA warns that early evidence shows links between prostate cancer drugs and diabetes. The Food and Drug Administration is looking into data suggesting a group of prostate cancer drugs increase the risk of diabetes and heart disease.

Abbott Labs profit tops forecasts on greater Humira sales, raises 2009 profit view. Abbott Laboratories said Wednesday it beat its own expectations for the third quarter as sales of its drug Humira continued to climb, along with sales of medical products and nutritional formula for children.